Results 181 to 190 of about 62,343 (221)
Memory B cell responses induced by pneumococcal conjugate vaccine schedules with fewer doses: analysis of a randomised-controlled trial in Viet Nam. [PDF]
Nat CommunOng DS +14 more
europepmc +1 more source
Correction to: Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. [PDF]
Clin Infect Diseuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Meningococcal conjugate vaccines
Expert Opinion on Pharmacotherapy, 2004Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis in the US, Europe and in many other parts of the world, including parts of sub-Saharan Africa (known as the African 'meningitis belt'). There are > 500000 cases of meningococcal disease annually with an estimated death toll of 135000 worldwide.
David S. Stephens, Shanta M. Zimmer
openaire +3 more sources
CONJUGATED POLYSACCHARIDE VACCINES
Infectious Disease Clinics of North America, 1999The joining of polysaccharide antigens to various proteins can result in increased immunogenicity of vaccines composed of such antigens. This article discusses conjugated polysaccharide vaccines for Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitis.
Edward K. Chapnick, Hussain Ahmad
openaire +3 more sources
Pneumococcal conjugate vaccines
Immunology Letters, 1991We have prepared conjugates of pneumococcal type 4 polysaccharides (PS4) or oligosaccharides to tetanus toxoid using the carbodiimide method. The use of a spacer, 6-aminohexanoic acid, resulted in higher incorporation of carrier protein. Conjugates contained up to 10% free polysaccharide, but no free protein.
Bart L. Haagmans +6 more
openaire +2 more sources